Journal of Thoracic Oncology

Papers
(The H4-Index of Journal of Thoracic Oncology is 56. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Genotype Versus Phenotype: Defining Predictive Biomarkers of Immunotherapy Response350
Board of Directors220
PP01.172 It's Never Too Late To Quit209
PP01.112 Treatment Patterns and Outcomes in Second-Line Advanced NSCLC Treated After Prior Platinum Chemotherapy and Immunotherapy Combination Therapy: A Real-World Study205
PP01.119 Real-World Use of Lurbinectedin in Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Updated Analysis164
PP01.26 Proprietary vs Open-Source Radiomic Platform for Lung Cancer Diagnosis142
In This Issue140
Why and When Do We Invasively Restage After Neoadjuvant Chemoimmunotherapy?135
Comment on “MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC”134
EP.02A.02 The Stroma Cell Function in the Border Region Between Lung Cancer and Normal Lung131
EP.09.05 Efficacy and Prognostic Factors of Radiotherapy in Brain Metastases From Non-Small Cell Lung Cancer Patients:A Retrospective Study125
OA01.04 Investigating the Association Between Procedure Duration of Coronary Angiography and Intervention and Postoperative Cancer Risk122
P1.11.03 Long-Term Efficacy of Immune Checkpoint Inhibitors in Pulmonary Cancer With Rhabdoid Features: A Single-Center Retrospective Analysis121
P2.15.17 Preliminary Results on Feasibility of Virtual Delivery of Exercise Therapy for Mitigation of Lung Cancer Decline118
P2.15.15 Impact of Palliative Care in Patients With Non-Small Cell Lung Cancer and Brain Metastases: A Retrospective Quality Analysis112
P1.11.04 Prediction of Overall Survival in Lung Cancer Patients With Different Organ Metastases: A SEER Population-Based Cohort Study108
EP.02.05 Three-Dimensional Visualization of Spreading Tumor Cell Through Air Spaces (STAS) Using High Resolution Phase-Contrast Imaging Method105
P3.16.09 A Study of Testing Knowledge Regarding Lung Cancer Screening Among General Population and Caregivers104
EP.13.08 Early Hospitalization During Chemoradiation for Limited-Stage Small Cell Lung Cancer Is Associated With Inferior Survival102
EP.12.06 Brilliant First Analysis: A Real-World Study of Characteristics and Safety About Brigatinib as First-Line for Chinese Patients With ALK+ NSCLC101
P3.12.09 Efficacy of Tepotinib Against Non-Adenocarcinoma MET Exon 14 Skipping NSCLC: A Subanalysis of the REAL-MET Study100
EP.04.42 Alunghive: Autonomous Registry and Analytics System to Transform Clinical Workflow and Enable Multicenter Lung Cancer Screening Research96
EP.16.07 Addressing Unmet Needs of the Lung Cancer Community: The Journey to Find and Implement Mind Over Matter95
P2.02.33 Radiotherapy Induces Ferroptosis and Activates STING Pathway to Reverse Immunotherapy Resistance in LKB1-Mutant Lung Cancer89
EP.13.20 Stereotactic Body Radiotherapy for Limited-Stage Small Cell Lung Cancer: Outcomes From a Single-Institution Retrospective Study89
P3.13.26 Sequencing of Stereotactic Body Radiation Therapy and Chemotherapy in Stage I Small Cell Lung Cancer: Practice Patterns and Outcomes89
P3.12.43 A Phase II Study of Sunvozertinib Combined With Anlotinib in NSCLC Patients Harboring EGFR Ex20Ins and Uncommon EGFR Mutations89
MA06.01 Real-World Outcomes of First-Line Immunotherapy Intensification of Patients With Advanced Non-Small Cell Lung Cancer (aNSCLC)87
EP.17.29 Real-World Effectiveness of Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) Without Oncogenic Driver Alteration87
OA10.02 Bevacizumab Plus Chemotherapy Versus Chemotherapy in Untreated Non-Squamous NSCLC With Brain Metastases: A Randomized, Phase 3 Study86
P1.17.27 Assessing Sarcopenia in Lung Cancer: Feasibility and Training Considerations of Using Quantitative Imaging Metrics From CT Scans84
P2.10.10 Soluble Ceacam5 Resistant ADC for Effective Tumor Targeted Delivery With Clinically Validated Tumor Selective Linker Payload80
P2.08.44 Adverse Cardiovascular Events Related to Immune Checkpoint Inhibitors in Staging IB-IIIb Non-Small Cell Lung Cancer: A Real-World Study79
EP.06.78 T Lymphocyte Subpopulations as Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Anti-Pd(L)1 Inhibitors78
EP.05.03 Analysis of Left Upper Pulmonary Arterial Bronchial Concomitant Consistency Based on Three-Dimensional Reconstruction73
EP.15.07 Living With Lung Cancer-A Qualitative Exploration of Its Psychosocial Impact72
P3.01.17 Age-Sex Disparities in Global Burden and Trend of Lung Cancer and Its Attributable Risk Factors in the United Kingdom From 1990-202172
EP.12.38 Firmonertinib(160Mg) Combined With Chemotherapy as First-Line Treatment for Advanced NSCLC Patients With EGFR Mutations and Cns Metastases72
EP.11.14 Impact of Bone Metastases on the Efficacy of First-Line Immunotherapy in Advanced NSCLC: An Analysis From a Prospective Real-World Study72
PT2.16.04 Advancing Lung Cancer Advocacy in Low- and Middle-Income Countries71
P3.13.02 The Effectiveness of Anatomical Versus Non-Anatomical Resection for Treatment of Small Cell Lung Carcinoma70
PT1.03.02 Single-Cell Profiling of Tumor Lineage Plasticity and the Immune Microenvironment in Transformed Small Cell Lung Cancer69
P3.12.36 Multicenter Retrospective Study of Selpercatinib Treatment for Advanced or Recurrent RET Fusion-Positive NSCLC in Japan69
P1.17.63 Docetaxel and Docetaxel Plus Ramucirumab Demonstrate Similar Real-World Overall Survival: A Contemporary Analysis68
EP.08D.06 Neoadjuvant Chemoimmunotherapy Does Not Increase Postoperative Morbidity of Pneumonectomy in NSCLC Patients: A Multi-Center Psmanalysis66
EP.01.19 Characteristics of Lung Cancer in Never- and Light-Smokers: A Retrospective Study From Greece66
P1.17.17 Financial Distress and Concerns Prior to Cancer-Directed Treatment Among Patients With NSCLC66
P1.08C.05 The Clinicopathological and Prognostic Significance of Skip-N2 Metastases: A Retrospective Multicenter Study65
P4.11E.02 Efficacy of Pembrolizumab Plus Pemetrexed in Older Patients with Non-squamous NSCLC According to PD-L1 Status from the CJLSG1901 Study64
EP.06D.02 Plasma-Derived Circulating Tumor DNA in Patients with Advanced EGFR-Positive Exon 20 NSCLC Treated With Osimertinib63
P2.17B.02 Healthcare Providers' Perceptions of Barriers and Enablers to Adopting New Surveillance Protocols62
EP.07F.06 Prospective Study of Breath Hold During SBRT Treatment of the Lung: Analysis Reliability of Surface Guidance Alone for Breath Hold61
EP.12A.10 Multi-Omics Uncovers Signatures Associated with Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Patients61
P2.17B.03 Improving Lung Cancer Screening Utilization and Efficiency Through a Patient-Centered Pathway with Virtual Visits60
EP.08F.18 Survival and Incidence Trends of Non-Small Cell Lung Cancer in Elderly Patients (>75 Years): Insights from SEER Database59
EP.11A.16 Infusion Timing of ICI Monotherapy in Patients with Advanced NSCLC: A Single Institution-Retrospective Study56
P1.01C.04 Key Stakeholder Priorities on Embedding Smoking Cessation Into Lung Cancer Screening: National Australian Consensus Workshop56
MA18.09 Comparing Efficient Lung Cancer Screening Strategies for Black and White Americans56
0.62002897262573